Bas Vastert

Associate Professor - medical

Strategic program(s):

Biography

Bas is a pediatric rheumatologist in the “EULAR center of excellence in rheumatology" Wilhelmina Children’s Hospital Utrecht. Besides being an esteemed clinician in the field of Pediatric Rheumatology, he has developed into a translational researcher, with a PhD on mechanisms of disease and therapy in severe JIA in 2013. From 2015, he has been starting a translational research group together with Jorg van Loosdregt, molecular biologist. They currently supervise 5 PhD students, 1 post-doc and 2 technicians together, within the Center of Translational Immunology in Utrecht (v Loosdregt-Vastert group). Their labgroup aims to translate cutting edge science into clinical benefit for patients and their research focusses on systemic JIA and on development of novel treatment strategies for JIA. Bas is currently leading a multi-center prospective trial implementing a biomarker driven stop-strategy for rIL-1RA therapy in systemic JIA in the Netherlands (the ESTIS trial).

In addition, as a designated Young Investigator, Bas is the Dutch lead for all translational laboratory studies within UCAN CAN DU (major infrastructural research project 2017-2021 in Canada and the Netherlands).

Key words: Translational research in childhood arthritis, biology of systemic JIA, (regulation of) auto-inflammation, regulation of autoimmune inflammation, epigenetics.

Strategic program(s):

Contact

bvastert@umcutrecht.nl

Pure profile

Research groups

Translational immunology

Research aim

It is our goal to improve the diagnosis and treatment of immune-related diseases with a focus on Juvenile Idiopathic Arthritis

Go to group

Recent publications

All publications

EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease Bruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, Sara Bindoli, Jordi Antón, Alexandre Belot, Claudia Bracaglia, Tamàs Constantin, Lorenzo Dagna, Alessandro Di Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei A. Grom, Yvan Jamilloux, Katerina Laskari, Calin Lazar, Francesca Minoia, Peter A. Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie Elise Truchetet, Sebastiaan J. Vastert, Tanita Christina Wilhelmer, Carine Wouters, Loreto Carmona, Fabrizio De Benedetti
Annals of the rheumatic diseases, 2024, vol. 83, p.1614-1627

Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis Sebastiaan J. Vastert, Susan P. Canny, Scott W. Canna, Rayfel Schneider, Elizabeth D. Mellins
Advances in Experimental Medicine and Biology, 2024, vol. 1448, p.323-353

Get Spliced Maurice J.H. van Haaren, Levina Bertina Steller, Sebastiaan J. Vastert, Jorg J.A. Calis, Jorg van Loosdregt
International Journal of Molecular Sciences, 2024, vol. 25

Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis Arto Ohinmaa, Jiabi Wen, Gillian R. Currie, Susanne M. Benseler, Joost F. Swart, Sebastiaan J. Vastert, Rae S.M. Yeung, Deborah A. Marshall
Quality of Life Research, 2024, vol. 33, p.2677-2691

Current treatment in macrophage activation syndrome worldwide Francesco Baldo, Remco G A Erkens, Mao Mizuta, Greta Rogani, Federica Lucioni, Claudia Bracaglia, Dirk Foell, Marco Gattorno, Marija Jelusic, Jordi Anton, Paul Brogan, Scott Canna, Shanmuganathan Chandrakasan, Randy Q Cron, Fabrizio De Benedetti, Alexei Grom, Merav Heshin-Bekenstein, AnnaCarin Horne, Raju Khubchandani, Seza Ozen, Pierre Quartier, Angelo Ravelli, Masaki Shimizu, Grant Schulert, Christiaan Scott, Rashmi Sinha, Nicolino Ruperto, Joost F Swart, Sebastiaan Vastert, Francesca Minoia,
Rheumatology (Oxford, England), 2024, vol. 64, p.32-44

CBP/P300 Inhibition Impairs CD4+ T Cell Activation Lucas Wilhelmus Picavet, Anoushka A K Samat, Jorg Calis, Lotte Nijhuis, Rianne Scholman, Michal Mokry, David F Tough, Rabinder K Prinjha, Sebastiaan J Vastert, Jorg van Loosdregt
Biomedicines, 2024, vol. 12

Fellowships & Awards

- 2007: Young investigator Meeting, Pediatric rheumatology European Society: Award for best basic abstract .

- 2014: Wilhelmina Research Fund (co-applicant), € 150 000 : Dissecting the complex role of S100-proteins in systemic juvenile idiopathic arthritis.

- 2015: ZonMW Rational Pharmacotherapy grant, € 340 000 : Biomarker guided treatment and stop strategy for rIL-1RA therapy in systemic JIA.

- 2016-2019: Wilhelmina Kinderziekenhuis Fonds, Rosenberg foundation / Vrienden WKZ (€340 000): Modulation of Treg in JIA by Nicotinamide. Principal Investigator, no overlap.

- 2016-2021: ZonMW grant, Rational Pharmacotherapy for implementation of biomarker guided tapering strategy of rIL-1RA in systemic JIA (€340 000 + €190 000 contribution Sobi). Principal Investigator, clinical trial, no overlap.

- 2017-2021: UCAN CAN DU: (8,0 mln Can$). Canada – Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic diseases. Young Investigator, NL lead for laboratory studies within UCAN CAN DU. (PI: R. Yeung, NM Wulffraat, co-PI JF Swart, S. Benseler).